Blood Cancer News and Research

RSS

New therapeutic target for patients with acute myeloid leukemia

According to a new study, targeting a pathway that is critical for the survival of some cases of acute myeloid leukemia could open up a new therapeutic route for patients.

3 May 2021

Genome architectural changes linked to B cell-related blood cancers

Flaws in the way chromosomes are packed into antibody-producing B-cells seem to play a key role in the development of B-cell-related blood cancers.

2 Feb 2021

Two enzymes drive pre-cancer stem cells into malignancy

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

From UC San Diego 27 Jan 2021

Investigational antisense medicine lowers disease burden, reduces myeloma cell abundance in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

From UC San Diego 21 Jan 2021

Study shows how specific gene mutations cause different types of diseases

Renowned cancer experts have resolved a query of how different types of mutations in a single gene are responsible for causing various types of diseases.

15 Jan 2021

New type of stem cell with regenerative abilities could soon become a reality

A new type of stem cell - that is, a cell with regenerative abilities - could be closer on the horizon, a new study led by UNSW Sydney shows.

From The University of New South Wales (UNSW) 15 Jan 2021

Combination method can boost immunotherapy for breast cancer

According to a new study performed by scientists from the University of North Carolina, stimulating an immune signaling pathway, which is best known for combating bacterial and viral infections, can increase the potential of genetically engineered T cells to remove breast cancer in mice.

4 Jan 2021

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020

Scientists identify mechanism involved in new precision cancer drug for blood cancers

University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published today in Nature Communications.

23 Oct 2020

New radioimmunotherapy effectively reverses resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

9 Oct 2020

Researchers establish new consortium to study the effect of mutations on the blood characteristics

A team of researchers has established an international consortium to analyze the blood of scores of people across the globe.

7 Sep 2020

A metabolic enzyme could be potential target for immunotherapies

The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system.

21 Aug 2020

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial led by researchers at UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston.

24 Jul 2020

Josep Carreras Institute creates spin-off to develop CAR-T based therapies for leukemia

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.

21 Jul 2020

Researchers identify key gene essential for leukemia stem cells' survival

Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

4 Jun 2020